News

The trial is designed to evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD. Around 120 patients with Huntington’s disease

The pricing is set at $0.25 per share for 144 restricted shares coupled with a one-year warrant for $0.50 per share to comprise a complete unit offering. The

The company is seeking approval of oritavancin is for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus

The new patent, entitled ‘Perivascular Mesenchymal Precursor Cell Induced Blood Vessel Formation’, provides the company with exclusive commercial rights in Europe initially through to 29 March 2024, with

Oculus executive vice president Bruce Thornton noted this is an extremely exciting time for the company since it’s the first Microcyn-based product approved anywhere in the world for

The novel treatment would use ‘off-the-shelf’ allogeneic adult stem cells, rather than requiring the extraction of a patient’s own stem cells that are then processed and reimplanted in

The cannabis manufacturer has developed both an extensive line of medicinal cannabis products as well as delivery technologies. This unique product line of topical cannabis lotion (cream or

The discoveries and innovations that will stem from this unique program will substantially benefit patients over the medium and long term by transforming medical practices in the treatment

AOP Orphan will actively call on customers in these additional markets to promote Brinavess. Cardiome chief commercial officer Karim Lalji noted making Brinavess available in significant Central/Eastern European